Starling Oncology (STLNW) Revenue (2021 - 2026)

Starling Oncology (STLNW) has reported Revenue for 6 consecutive years, with $161.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue rose 34.62% year-over-year to $161.3 million; the trailing twelve-month figure through Jun 2026 stood at $587.2 million (up 38.38% YoY), and the FY2025 full-year result was $502.7 million, up 27.79% from the prior year.
• Revenue improved to $161.3 million in Q2 2026 per STLNW's latest filing, from $147.4 million in the prior quarter.
• Across five years, Revenue topped out at $161.3 million in Q2 2026 and bottomed at $55.2 million in Q1 2022.
• Historically, Revenue has averaged $99.0 million across 5 years, with a median of $96.6 million in 2024.
• The widest YoY moves for Revenue: up 41.58% in 2025, down 10.29% in 2025.
• Over 5 years, Revenue stood at $71.4 million in 2022, then grew by 20.11% to $85.8 million in 2023, then grew by 16.88% to $100.3 million in 2024, then jumped by 41.58% to $142.0 million in 2025, then climbed by 13.61% to $161.3 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $161.3 million, $147.4 million, and $142.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.